low - Rare disease treatments for life-threatening conditions exhibit minimal demand elasticity regardless of economic conditions. Patient populations are medically driven rather than discretionary, with payer coverage through commercial insurance and Medicaid insulating from consumer spending cycles. However, state Medicaid budget pressures during recessions can delay reimbursement approvals.

Rising rates negatively impact valuation multiples for pre-profitable biotech as discount rates increase on future cash flows. Higher rates increase cost of capital for future equity raises needed to fund operations given $100M+ annual cash burn. Debt financing becomes more expensive though company maintains modest 0.47x debt/equity ratio. Rate environment affects M&A likelihood as strategic acquirers face higher financing costs.

growth - Attracts speculative biotech investors focused on binary regulatory catalysts and rare disease commercial potential. Small market cap ($500M) and negative cash flow profile appeal to venture-style investors willing to accept high risk for potential multi-bagger returns on successful drug approvals. Not suitable for value or income investors given lack of profitability and dividends.